Vascular dysfunction as a cause of endometrial bleeding

Gynecological Endocrinology

Volumn 28, Issue 9, 2012, Pages 688-693

  Archer, David F ^a  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Endometrial spotting and bleeding; Heavy menstrual bleeding; Hormonal contraceptives; Medical therapy

Indexed keywords

ALPHA TOCOPHEROL; ANTIFIBRINOLYTIC AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOXYCYCLINE; ESTROGEN; FIBRIN; GELATINASE B; GESTAGEN; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; MIFEPRISTONE; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE; PROSTAGLANDIN E2; STROMELYSIN; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UROKINASE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 3; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ARTICLE; BLOOD VESSEL WALL; DRUG EFFICACY; DRUG TREATMENT FAILURE; DYSMENORRHEA; ENDOMETRIUM; HEAVY MENSTRUAL BLEEDING; HEMOSTASIS; LEUKOCYTE; MENORRHAGIA; MENSTRUATION; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULAR DYSFUNCTION; VASOCONSTRICTION; VASODILATATION;

CONTRACEPTIVES, ORAL, SYNTHETIC; ENDOMETRIUM; FEMALE; HUMANS; LEVONORGESTREL; MENORRHAGIA; METRORRHAGIA;

EID: 84865309219     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2011.588848     Document Type: Article

References (67)

1. Livingstone M, Fraser IS. Mechanisms of abnormal uterine bleeding. Hum Reprod Update 2002;8:60-67. (Pubitemid 34144986)
2. Salamonsen LA. Current concepts of the mechanisms of menstruation: a normal process of tissue destruction. Trends Endocrinol Metab 1998;9:305-309. (Pubitemid 28471339)
3. Salamonsen LA. Tissue injury and repair in the female human reproductive tract. Reproduction 2003;125:301-311. (Pubitemid 36395578)
4. Garry R, Hart R, Karthigasu KA, Burke C. A re-appraisal of the morphological changes within the endometrium during menstruation: a hysteroscopic, histological and scanning electron microscopic study. Hum Reprod 2009;24:1393-1401.
5. Slayden OD, Brenner RM. A critical period of progesterone withdrawal precedes menstruation in macaques. Reprod Biol Endocrinol 2006;4 Suppl 1:S6.
6. Brenner RM, Nayak NR, Slayden OD, Critchley HO, Kelly RW. Premenstrual and menstrual changes in the macaque and human endometrium: relevance to endometriosis. Ann N Y Acad Sci 2002;955:60-74; discussion 86-88, 396-406. (Pubitemid 34271063)
7. Ferenczy A. Pathophysiology of endometrial bleeding. Maturitas 2003;45:1-14. (Pubitemid 36712887)
8. Christiaens GC, Sixma JJ, Haspels AA. Morphology of haemostasis in menstrual endometrium. Br J Obstet Gynaecol 1980;87:425-439. (Pubitemid 10068506)
9. Christiaens GC, Sixma JJ, Haspels AA. Hemostasis in menstrual endometrium: a review. Obstet Gynecol Surv 1982;37:281-303. (Pubitemid 14236385)
10. Hallberg L, Hogdahl AM, Nilsson L, Rybo G. Menstrual blood loss - a population study. Variation at different ages and attempts to define normality. Acta Obstet Gynecol Scand 1966;45:320-351.
11. Ferenczy A. Studies on the cytodynamics of human endometrial regeneration. I. Scanning electron microscopy. Am J Obstet Gynecol 1976;124:64-74.
12. Fan X, Krieg S, Kuo CJ, Wiegand SJ, Rabinovitch M, Druzin ML, Brenner RM, Giudice LC, Nayak NR. VEGF blockade inhibits angiogenesis and reepithelialization of endometrium. FASEB J 2008;22:3571-3580.
13. Garry R, Hart R, Karthigasu KA, Burke C. Structural changes in endometrial basal glands during menstruation. BJOG;117:1175-1185.
14. Salamonsen LA, Kovacs GT, Findlay JK. Current concepts of the mechanisms of menstruation. Baillieres Best Pract Res Clin Obstet Gynaecol 1999;13:161-179. (Pubitemid 29353803)
15. Salamonsen LA, Lathbury LJ. Endometrial leukocytes and menstruation. Hum Reprod Update 2000;6:16-27. (Pubitemid 30099339)
16. Salamonsen LA, Zhang J, Brasted M. Leukocyte networks and human endometrial remodelling. J Reprod Immunol 2002;57:95-108. (Pubitemid 35245742)
17. Kelly RW, King AE, Critchley HO. Inflammatory mediators and endometrial function-focus on the perivascular cell. J Reprod Immunol 2002;57:81-93. (Pubitemid 35245741)
18. Dong JC, Dong H, Campana A, Bischof P. Matrix metalloproteinases and their specific tissue inhibitors in menstruation. Reproduction 2002;123:621-631. (Pubitemid 34498336)
19. Salamonsen LA, Woolley DE. Menstruation: induction by matrix metalloproteinases and inflammatory cells. J Reprod Immunol 1999;44:1-27. (Pubitemid 29457769)
20. Fressinaud E, Baruch D, Girma JP, Sakariassen KS, Baumgartner HR, Meyer D. von Willebrand factor-mediated platelet adhesion to collagen involves platelet membrane glycoprotein IIb-IIIa as well as glycoprotein Ib. J Lab Clin Med 1988;112:58-67.
21. Sakariassen KS, Fressinaud E, Girma JP, Meyer D, Baumgartner HR. Role of platelet membrane glycoproteins and von Willebrand factor in adhesion of platelets to subendothelium and collagen. Ann N Y Acad Sci 1987;516:52-65.
22. Zorio E, Gilabert-Estelles J, Espana F, Ramon LA, Cosin R, Estelles A. Fibrinolysis: the key to new pathogenetic mechanisms. Curr Med Chem 2008;15:923-929. (Pubitemid 351736413)
23. Farquhar C, Brown J. Oral contraceptive pill for heavy menstrual bleeding. Cochrane Database Syst Rev 2009: CD000154.
24. Stewart EA. Uterine fibroids. Lancet 2001;357:293-298. (Pubitemid 32120866)
25. Pron G, Cohen M, Soucie J, Garvin G, Vanderburgh L, Bell S. The Ontario Uterine Fibroid Embolization Trial. Part 1. Baseline patient characteristics, fibroid burden, and impact on life. Fertil Steril 2003;79:112-119. (Pubitemid 36071248)
26. Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 2003;126:559-567. (Pubitemid 37540615)
27. Cooke I, Lethaby A, Farquhar C. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000: CD000249.
28. American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG committee opinion. No. 337: noncontraceptive uses of the levonorgestrel intrauterine system. Obstet Gynecol 2006;107:1479-1482.
29. Cameron IT. The levonorgestrel intrauterine system: the benefits of reduced bleeding. Eur J Contracept Reprod Health Care 2001;6 Suppl 1:27-32.
30. Luukkainen T. The levonorgestrel intrauterine system: therapeutic aspects. Steroids 2000;65:699-702.
31. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD001016.
32. Lethaby A, Irvine G, Cameron I. Cyclical progestogens for heavy menstrual bleeding. Cochrane Database Syst Rev 2008:CD001016.
33. Smith OP, Jabbour HN, Critchley HO. Cyclooxygenase enzyme expression and E series prostaglandin receptor signalling are enhanced in heavy menstruation. Hum Reprod 2007;22:1450-1456. (Pubitemid 47062818)
34. Catalano RD, Wilson MR, Boddy SC, Jabbour HN. Comprehensive expression analysis of prostanoid enzymes and receptors in the human endometrium across the menstrual cycle. Mol Hum Reprod 2011;17:182-192.
35. Jabbour HN, Sales KJ, Smith OP, Battersby S, Boddy SC. Prostaglandin receptors are mediators of vascular function in endometrial pathologies. Mol Cell Endocrinol 2006;252:191-200.
36. Lethaby A, Augood C, Duckitt K. Nonsteroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD000400.
37. Lethaby A, Augood C, Duckitt K. Nonsteroidal antiinflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2002:CD000400.
38. Lethaby A, Augood C, Duckitt K, Farquhar C. Nonsteroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev 2007:CD000400.
39. Maia H Jr, Casoy J, Pimentel K, Correia T, Athayde C, Cruz T, Coutinho EM. Effect of oral contraceptives on vascular endothelial growth factor, Cox-2 and aromatase expression in the endometrium of uteri affected by myomas and associated pathologies. Contraception 2008;78:479-485.
40. Maia H, Correia T, Freitas L, Athayde C, Coutinho EM. Cyclooxygenase-2 expression in the endometrium and its relationship to bleeding in users of continuous oral contraceptives. Gynecol Endocrinol 2006;22:96-100.
41. Maia H Jr, Maltez A, Studard E, Zausner B, Athayde C, Coutinho E. Effect of the menstrual cycle and oral contraceptives on cyclooxygenase-2 expression in the endometrium. Gynecol Endocrinol 2005;21:57-61. (Pubitemid 41097797)
42. Guttinger A, Critchley HO. Endometrial effects of intrauterine levonorgestrel. Contraception 2007;75:S93-S98. (Pubitemid 46770709)
43. Stephanie R, Labied S, Blacher S, Frankenne F, Munaut C, Fridman V, Beliard A, Foidart J-M, Nisolle M. Endometrial vessel maturation in women exposed to levonorgestrelreleasing intrauterine system for a short or prolonged period of time. Hum Reprod 2007;22:3084-3091. (Pubitemid 351696764)
44. Jondet M, Letellier B, Verdys MT. Endometrial vascularization in levonorgestrel intrauterine device users; computerized microvessel measurement study. Contraception 2005;71:60-64. (Pubitemid 41583151)
45. Moller B, Ronnerdag M, Wang G, Odlind V, Olovsson M. Expression of vascular endothelial growth factors and their receptors in human endometrium from women experiencing abnormal bleeding patterns after prolonged use of a levonorgestrel- releasing intrauterine system. Hum Reprod 2005;20: 1410-1417. (Pubitemid 40790272)
46. Charnock-Jones DS, Macpherson AM, Archer DF, Leslie S, Makkink WK, Sharkey AM, Smith SK. The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod 2000;15 Suppl 3:85-95.
47. Lau TM, Affandi B, Rogers PA. The effects of levonorgestrel implants on vascular endothelial growth factor expression in the endometrium. Mol Hum Reprod 1999;5:57-63. (Pubitemid 29045641)
48. Roopa BA, Loganath A, Singh K. The effect of a levonorgestrel- releasing intrauterine system on angiogenic growth factors in the endometrium. Hum Reprod 2003;18:1809-1819. (Pubitemid 37107552)
49. Archer DF, Navarro FJ, Leslie S, Mirkin S. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, and 17beta-estradiol on vascular endothelial growth factor isomers 121 and 165 in Ishikawa cells. Fertil Steril 2004;81:165-170. (Pubitemid 38058343)
50. Mirkin S, Archer DF. Effects of levonorgestrel, medroxyprogesterone acetate, norethindrone, progesterone, and 17betaestradiol on thrombospondin-1 mRNA in Ishikawa cells. Fertil Steril 2004;82:220-222. (Pubitemid 38968804)
51. Mirkin S, Navarro F, Archer DF. Hormone therapy and endometrial angiogenesis. Climacteric 2003;6:273-277. (Pubitemid 38112896)
52. Lethaby AE, Cooke I, Rees M. Progesterone or progestogenreleasing intrauterine systems for heavy menstrual bleeding. Cochrane Database Syst Rev 2005:CD002126.
53. Blumenthal PD, Dawson L, Hurskainen R. Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine system. Int J Gynaecol Obstet;112:171-178.
54. Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274-277. (Pubitemid 24074449)
55. Dockeray CJ, Sheppard BL, Daly L, Bonnar J. The fibrinolytic enzyme system in normal menstruation and excessive uterine bleeding and the effect of tranexamic acid. Eur J Obstet Gynecol Reprod Biol 1987;24:309-318. (Pubitemid 17065272)
56. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding. Cochrane Database Syst Rev 2000:CD000249.
57. Abdel-Aleem H, d'Arcangues C, Vogelsong K, Gulmezoglu AM. Treatment of vaginal bleeding irregularities induced by progestin-only contraceptives. Cochrane Database Syst Rev 2007:CD003449.
58. Gallo MF, Nanda K, Grimes DA, Schulz KF. Twenty micrograms vs.420 microg estrogen oral contraceptives for contraception: systematic review of randomized controlled trials. Contraception 2005;71:162-169. (Pubitemid 40250196)
59. Gallo MF, Nanda K, Grimes DA, Schulz KF. 20 mcg versus420 mcg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005: CD003989.
60. Maia H Jr, Casoy J, Athayde C, Valente Filho J, Coutinho EM. The effect of a continuous regimen of drospirenone 3 mg/ ethinylestradiol 30 microg on Cox-2 and Ki-67 expression in the endometrium. Eur J Contracept Reprod Health Care;15:35-40.
61. Maia H Jr, Casoy J, Correia T, Freitas L, Pimentel K, Athayde C, Coutinho E. Effect of the menstrual cycle and oral contraceptives on aromatase and cyclooxygenase-2 expression in adenomyosis. Gynecol Endocrinol 2006;22:547-551. (Pubitemid 44885093)
62. Grimes DA, Lopez LM, O'Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2010:CD007541.
63. Benagiano G, Primiero FM. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann N Y Acad Sci 2003;997:163-173. (Pubitemid 38491072)
64. Hickey M, Fraser IS. Surface vascularization and endometrial appearance in women with menorrhagia or using levonorgestrel contraceptive implants. Implications for the mechanisms of breakthrough bleeding. Hum Reprod 2002;17:2428-2434. (Pubitemid 35021470)
65. Rogers PA, Plunkett D, Affandi B. Perivascular smooth muscle alpha-actin is reduced in the endometrium of women with progestin-only contraceptive breakthrough bleeding. Hum Reprod 2000;15 Suppl 3:78-84.
66. Weisberg E, Hickey M, Palmer D, O'Connor V, Salamonsen LA, Findlay JK, Fraser IS. A randomized controlled trial of treatment options for troublesome uterine bleeding in Implanon users. Hum Reprod 2009;24:1852-1861.
67. Jain JK, Nicosia AF, Nucatola DL, Lu JJ, Kuo J, Felix JC. Mifepristone for the prevention of breakthrough bleeding in new starters of depo-medroxyprogesterone acetate. Steroids 2003;68:1115-1119. (Pubitemid 37532438)